Tags

Type your tag names separated by a space and hit enter

SOX1 antibodies in sera from patients with paraneoplastic neurological syndromes.
Acta Neurol Scand. 2012 May; 125(5):326-31.AN

Abstract

OBJECTIVES

SOX1 antibodies have been described in patients with Lambert-Eaton myasthenic syndrome (LEMS) in association with voltage-gated calcium channel antibodies as serological markers of small cell lung cancer (SCLC). This study was aimed to screen for additional SOX1 autoimmunity in onconeural antibody-positive sera from patients with paraneoplastic neurological syndromes (PNS) other than LEMS and to identify the clinical-immunological profile and associated tumours of patients with coexisting SOX1 antibodies.

METHODS

We retrospectively analysed sera from 55 patients with different PNS positive for well-characterized antineuronal antibodies for the presence of SOX1 antibodies by recombinant ELISA and immunoblot.

RESULTS

Eight (14.5%) patients showed additional SOX1 antibodies in the ELISA and the recombinant immunoblot. Five patients had coexisting Hu antibodies, while the other three showed coexisting CV2/CRMP5, amphiphysin, and coexisting CV2/CRMP5 and Hu antibodies, respectively. PNS included (partially overlapping) subacute sensory neuropathy, subacute sensorimotor neuropathy, cerebellar degeneration, brainstem encephalitis, encephalomyelitis and limbic encephalitis. No tumour was detected in two patients, while the others had lung cancer (four SCLC and two non-SCLC). One patient showed SOX1-specific intrathecal antibody synthesis.

CONCLUSIONS

We describe SOX1 reactivity for the first time overlapping with CV2/CRMP5 and amphiphysin antibodies. SOX1 reactivity is predominantly associated with Hu antibodies and SCLC, but can occur also in other types of lung cancer. Neurological manifestations present in patients with coexisting SOX1 antibodies and well-characterized antineuronal antibodies do not differ from those previously described in patients positive for antineuronal antibodies but no SOX1-specific anti-glial antibodies.

Authors+Show Affiliations

Department of Neurology, Albert Ludwigs University, Freiburg, Germany. oliver.stich@uniklinik-freiburg.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

21751968

Citation

Stich, O, et al. "SOX1 Antibodies in Sera From Patients With Paraneoplastic Neurological Syndromes." Acta Neurologica Scandinavica, vol. 125, no. 5, 2012, pp. 326-31.
Stich O, Klages E, Bischler P, et al. SOX1 antibodies in sera from patients with paraneoplastic neurological syndromes. Acta Neurol Scand. 2012;125(5):326-31.
Stich, O., Klages, E., Bischler, P., Jarius, S., Rasiah, C., Voltz, R., & Rauer, S. (2012). SOX1 antibodies in sera from patients with paraneoplastic neurological syndromes. Acta Neurologica Scandinavica, 125(5), 326-31. https://doi.org/10.1111/j.1600-0404.2011.01572.x
Stich O, et al. SOX1 Antibodies in Sera From Patients With Paraneoplastic Neurological Syndromes. Acta Neurol Scand. 2012;125(5):326-31. PubMed PMID: 21751968.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - SOX1 antibodies in sera from patients with paraneoplastic neurological syndromes. AU - Stich,O, AU - Klages,E, AU - Bischler,P, AU - Jarius,S, AU - Rasiah,C, AU - Voltz,R, AU - Rauer,S, Y1 - 2011/07/14/ PY - 2011/7/15/entrez PY - 2011/7/15/pubmed PY - 2012/12/10/medline SP - 326 EP - 31 JF - Acta neurologica Scandinavica JO - Acta Neurol. Scand. VL - 125 IS - 5 N2 - OBJECTIVES: SOX1 antibodies have been described in patients with Lambert-Eaton myasthenic syndrome (LEMS) in association with voltage-gated calcium channel antibodies as serological markers of small cell lung cancer (SCLC). This study was aimed to screen for additional SOX1 autoimmunity in onconeural antibody-positive sera from patients with paraneoplastic neurological syndromes (PNS) other than LEMS and to identify the clinical-immunological profile and associated tumours of patients with coexisting SOX1 antibodies. METHODS: We retrospectively analysed sera from 55 patients with different PNS positive for well-characterized antineuronal antibodies for the presence of SOX1 antibodies by recombinant ELISA and immunoblot. RESULTS: Eight (14.5%) patients showed additional SOX1 antibodies in the ELISA and the recombinant immunoblot. Five patients had coexisting Hu antibodies, while the other three showed coexisting CV2/CRMP5, amphiphysin, and coexisting CV2/CRMP5 and Hu antibodies, respectively. PNS included (partially overlapping) subacute sensory neuropathy, subacute sensorimotor neuropathy, cerebellar degeneration, brainstem encephalitis, encephalomyelitis and limbic encephalitis. No tumour was detected in two patients, while the others had lung cancer (four SCLC and two non-SCLC). One patient showed SOX1-specific intrathecal antibody synthesis. CONCLUSIONS: We describe SOX1 reactivity for the first time overlapping with CV2/CRMP5 and amphiphysin antibodies. SOX1 reactivity is predominantly associated with Hu antibodies and SCLC, but can occur also in other types of lung cancer. Neurological manifestations present in patients with coexisting SOX1 antibodies and well-characterized antineuronal antibodies do not differ from those previously described in patients positive for antineuronal antibodies but no SOX1-specific anti-glial antibodies. SN - 1600-0404 UR - https://www.unboundmedicine.com/medline/citation/21751968/SOX1_antibodies_in_sera_from_patients_with_paraneoplastic_neurological_syndromes_ L2 - https://doi.org/10.1111/j.1600-0404.2011.01572.x DB - PRIME DP - Unbound Medicine ER -